Ehninger G, Proksch B, Heinzel G, Schiller E, Weible K H, Woodward D L
Invest New Drugs. 1985;3(2):109-16. doi: 10.1007/BF00174157.
An HPLC method using paired-ion chromatography on RP C-18 material was developed. After sample clean up on XAD columns, mitoxantrone (Novantrone; dihydroxyanthracenedione) in concentrations below 1 ng/ml in serum and 0.2 ng/ml in urine were measurable with a coefficient of variation less than 9.3% at a wavelength of 658 nm. Four metabolites were separated in urine. The major metabolite cochromatographed with the synthesized dicarboxylic acid of mitoxantrone. Within 48 hours 4.4% of the administered dose was excreted in urine as mitoxantrone, 0.5% as metabolite 1 and 0.3% as metabolite 2. The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214.8 hours, and a volume of distribution (ss) of 3792 litres. The total body clearance was 358 ml/min and the renal clearance was 26.2 ml/min.
开发了一种在RP C-18材料上使用配对离子色谱法的高效液相色谱法。在XAD柱上对样品进行净化后，在658nm波长下，血清中浓度低于1ng/ml、尿液中浓度低于0.2ng/ml的米托蒽醌（诺维本；二羟基蒽二酮）可被检测到，变异系数小于9.3%。在尿液中分离出了四种代谢物。主要代谢物与合成的米托蒽醌二羧酸共色谱。在48小时内，给药剂量的4.4%以米托蒽醌形式经尿液排出，0.5%以代谢物1形式排出，0.3%以代谢物2形式排出。药代动力学参数可用三室模型充分描述，终末半衰期为214.8小时，分布容积（稳态）为3792升。总体清除率为358ml/min，肾清除率为26.2ml/min。
